

Patent Application
Attorney Docket No. PC10332C

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, Box Amendments, P. O. Box 1450, Alexandria, VA 22313-1450 on this 6th day of March 2006.

By

Kelly A. Smith
(Signature of person mailing)

Kelly A. Smith

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Eric B. Grossman, et al. :

APPLICATION NO.: 10/731,905 : Examiner: Leslie A. Royds

FILING DATE: December 10, 2003 : Group Art Unit: 1614

TITLE: TREATMENT OF NEUROPATHY :

Hon. Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.


It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

The Commissioner is hereby authorized to charge the sum of \$180.00 to Deposit Account No. 16-1445 to cover the cost of this submission in accordance with 37 CFR 1.97(c) and 1.17(p). The Commissioner is further authorized to charge any additional fees which may be required under 37 CFR 1.16 and 1.17, or credit any overpayment, to Account No. 16-1445.

A prompt and favorable response is earnestly solicited.

Date: 3/6/06

Respectfully submitted,



A. Dean Olson
Attorney for Applicant(s)
Reg. No. 31,185

Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 441-4904

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				ATTY. DOCKET NO. PC10332C				SERIAL NO. 10/731,905			
APPLICANT Eric B. Grossman, et al.											
FILING DATE December 10, 2003								GROUP 1614			

U.S. PATENT DOCUMENTS												
DOCUMENT NUMBER								DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS													
DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
												YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)											
			Diabetologia, Vol. 38, Supplement 1, p. A262 (1995)								
			Saeki, T., et al., "Isolation of Cyclic Nucleotide Phosphodiesterase Isozymes from Pig Aorta", <i>Biochemical Pharmacology</i> , Vol. 46, No. 5, pp. 833-839 (1993)								
			Horowitz, S., "Diabetic Neuropathy", <i>Clinical Orthopaedics and Related Research</i> , No. 296, pp. 78-85 (1993)								
			Lalau, J.D., et al., "Pathogénie des neuropathies diabétiques", <i>Annales de Medecine Interne</i> , Vol. 136, No. 6, pp. 486-495 (1985)								
			Flynn, M.D., et al., "Diabetic Neuropathy and the Microcirculation", <i>Diabetic Medicine</i> , Vol. 12, No. 4, pp. 298-301 (1995)								
			Stevens, M.J., et al., "The Aetiology of Diabetic Neuropathy: the Combined Roles of Metabolic and Vascular Defects", <i>Diabetic Medicine</i> , Vol. 12, No. 7, pp. 566-579 (1995)								
			McMillan, D., "The Microcirculation in Diabetes", <i>Microcirculation, Endothelium and Lymphatics</i> , Vol. 1, pp. 3-24 (1984)								
			Cavallerano, J., "Ocular Manifestations of Diabetes Mellitus", <i>Optometry Clinics</i> , Vol. 2, No. 2, pp. 93-116 (1992)								

EXAMINER 	DATE CONSIDERED
-----------------------------	------------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.